s
i
ANANBIOANAL - 2010
Pharmaceutical R & D Summit
doi:10.4172/2155-9872.1000018
A New Frontier on Toxicological Studies on Central Nervous
System
Sanjita Das
Department of Pharmaceutical Technology, Noida Institute of Engineering and Technology, Greater Noida, UP, India
A
fter gaining relevant information on the harmful effects of a compound, the
levels for its safe usage or the degree of its safeness is established. A wide
range of toxicological studies are being undertaken as per national and International
guidelines. Out of which the toxicological studies on Central Nervous System
becoming the area of attraction. The present study highlights the possible CNS
toxicities with a drug entity and their prevention and treatment. Fluoroquinolones
can induce a wide range of serious adverse psychiatric effects showing depressant
activity on the CNS. Its concomitant use of NSAIDs may increase seizure risk.
Neurologic complications of cancer therapy are an increasingly important concern
in patient management. Prompt recognition of these problems and their causes will
have an impact on patient care in all areas of oncology. It is not surprising that clinical
trails evaluating Biological Response Modifiers have also demonstrated that CNS
toxicity is very common. The role of amifostine (WR-2721) in ameliorating radiation-
induced central nervous system (CNS) toxicity is effective. Greater awareness of
severe and complex CNS neurotoxicity even with low dose Cyclosporin A treatment
in rheumatoid arthritis is of the utmost importance and so with Ciprofloxacin. Central
nervous system (CNS) toxicity of tricyclic antidepressants (TCAs) is serious, costly,
frequent, and difficult to diagnose early in its course. CNS lidocaine toxicity is
biphasic and the most common cause for it is dosing error. This study concludes that
the CNS toxicological studies of any new chemical entity will lead to its better use
for the ailment of different diseases of mankind. Additional studies are warranted
to investigate the protective effect with differing regimens of administration, more
clinically relevant fractionation regimens and longer follow-up.
ANALBIOANAL-2010
O
M
I
C
S
P
i
u
h
b
l
n
g
G
r
o
u
p